Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Potential biomarkers to predict outcome of faecal microbiota transfer for recurrent Clostridioides difficile infection.

Farowski F, Solbach P, Tsakmaklis A, Brodesser S, Cruz Aguilar MR, Cornely OA, Dettmer K, Higgins PG, Suerbaum S, Jazmati N, Oefner PJ, Vehreschild MJGT; German Clinical Microbiome Study Group (GCMSG).

Dig Liver Dis. 2019 Jan 26. pii: S1590-8658(19)30040-4. doi: 10.1016/j.dld.2019.01.012. [Epub ahead of print]

PMID:
30770201
2.

Impact of single-room contact precautions on hospital-acquisition and transmission of multidrug-resistant Escherichia coli: a prospective multicentre cohort study in haematological and oncological wards.

Biehl LM, Higgins P, Wille T, Peter K, Hamprecht A, Peter S, Dörfel D, Vogel W, Häfner H, Lemmen S, Panse J, Rohde H, Klupp EM, Schafhausen P, Imirzalioglu C, Falgenhauer L, Salmanton-García J, Stecher M, Vehreschild JJ, Seifert H, Vehreschild MJGT.

Clin Microbiol Infect. 2019 Jan 12. pii: S1198-743X(18)30840-1. doi: 10.1016/j.cmi.2018.12.029. [Epub ahead of print]

PMID:
30641228
3.

Prognostic factors in 264 adults with invasive Scedosporium spp. and Lomentospora prolificans infection reported in the literature and FungiScope®.

Seidel D, Meißner A, Lackner M, Piepenbrock E, Salmanton-García J, Stecher M, Mellinghoff S, Hamprecht A, Durán Graeff L, Köhler P, Cheng MP, Denis J, Chedotal I, Chander J, Pakstis DL, Los-Arcos I, Slavin M, Montagna MT, Caggiano G, Mares M, Trauth J, Aurbach U, Vehreschild MJGT, Vehreschild JJ, Duarte RF, Herbrecht R, Wisplinghoff H, Cornely OA.

Crit Rev Microbiol. 2019 Jan 10:1-21. doi: 10.1080/1040841X.2018.1514366. [Epub ahead of print] Erratum in: Crit Rev Microbiol. 2019 Feb 18;:1.

PMID:
30628529
4.

Incidence of infections due to third generation cephalosporin-resistant Enterobacteriaceae - a prospective multicentre cohort study in six German university hospitals.

Rohde AM, Zweigner J, Wiese-Posselt M, Schwab F, Behnke M, Kola A, Obermann B, Knobloch JK, Feihl S, Querbach C, Gebhardt F, Mischnik A, Ihle V, Schröder W, Armean S, Peter S, Tacconelli E, Hamprecht A, Seifert H, Vehreschild MJGT, Kern WV, Gastmeier P; DZIF-ATHOS study group.

Antimicrob Resist Infect Control. 2018 Dec 27;7:159. doi: 10.1186/s13756-018-0452-8. eCollection 2018.

5.

An Open-Labeled Study on Fecal Microbiota Transfer in Irritable Bowel Syndrome Patients Reveals Improvement in Abdominal Pain Associated with the Relative Abundance of Akkermansia Muciniphila.

Cruz-Aguliar RM, Wantia N, Clavel T, Vehreschild MJGT, Buch T, Bajbouj M, Haller D, Busch D, Schmid RM, Stein-Thoeringer CK.

Digestion. 2018 Nov 13:1-12. doi: 10.1159/000494252. [Epub ahead of print]

PMID:
30423561
6.

Healthcare burden of probable and proven invasive mucormycosis: a multi-centre cost-of-illness analysis of patients treated in tertiary care hospitals between 2003 and 2016.

Heimann SM, Vehreschild MJGT, Cornely OA, Heinz WJ, Grüner B, Silling G, Kessel J, Seidel D, Vehreschild JJ.

J Hosp Infect. 2019 Mar;101(3):339-346. doi: 10.1016/j.jhin.2018.11.003. Epub 2018 Nov 10.

PMID:
30423409
7.

Correction to: Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE).

Vehreschild MJGT, Taori S, Goldenberg SD, Thalhammer F, Bouza E, van Oene J, Wetherill G, Georgopali A.

Eur J Clin Microbiol Infect Dis. 2019 Jan;38(1):199. doi: 10.1007/s10096-018-3410-8.

8.

Vancomycin-resistant enterococci (VRE): a reason to isolate?

Vehreschild MJGT, Haverkamp M, Biehl LM, Lemmen S, Fätkenheuer G.

Infection. 2019 Feb;47(1):7-11. doi: 10.1007/s15010-018-1202-9. Epub 2018 Sep 3. Review.

PMID:
30178076
9.

Assessment of urinary 3-indoxyl sulfate as a marker for gut microbiota diversity and abundance of Clostridiales.

Farowski F, Els G, Tsakmaklis A, Higgins PG, Kahlert CR, Stein-Thoeringer CK, Bobardt JS, Dettmer-Wilde K, Oefner PJ, Vehreschild JJ, Vehreschild MJGT.

Gut Microbes. 2018 Aug 17:1-9. doi: 10.1080/19490976.2018.1502536. [Epub ahead of print]

PMID:
30118620
10.

Fecal microbiota transplantation in a kidney transplant recipient with recurrent urinary tract infection.

Biehl LM, Cruz Aguilar R, Farowski F, Hahn W, Nowag A, Wisplinghoff H, Vehreschild MJGT.

Infection. 2018 Dec;46(6):871-874. doi: 10.1007/s15010-018-1190-9. Epub 2018 Aug 14.

PMID:
30109576
11.

Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE).

Vehreschild MJGT, Taori S, Goldenberg SD, Thalhammer F, Bouza E, van Oene J, Wetherill G, Georgopali A.

Eur J Clin Microbiol Infect Dis. 2018 Nov;37(11):2097-2106. doi: 10.1007/s10096-018-3344-1. Epub 2018 Aug 11. Erratum in: Eur J Clin Microbiol Infect Dis. 2019 Jan;38(1):199.

12.

BaiCD gene cluster abundance is negatively correlated with Clostridium difficile infection.

Solbach P, Chhatwal P, Woltemate S, Tacconelli E, Buhl M, Gerhard M, Thoeringer CK, Vehreschild MJGT, Jazmati N, Rupp J, Manns MP, Bachmann O, Suerbaum S.

PLoS One. 2018 May 8;13(5):e0196977. doi: 10.1371/journal.pone.0196977. eCollection 2018.

13.

Evaluation of the Use of Rectal Swabs for Laboratory Diagnosis of Clostridium difficile Infection.

Jazmati N, Kirpal E, Piepenbrock E, Stelzer Y, Vehreschild MJGT, Seifert H.

J Clin Microbiol. 2018 Jun 25;56(7). pii: e00426-18. doi: 10.1128/JCM.00426-18. Print 2018 Jul.

14.

Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors-Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO).

Rieger CT, Liss B, Mellinghoff S, Buchheidt D, Cornely OA, Egerer G, Heinz WJ, Hentrich M, Maschmeyer G, Mayer K, Sandherr M, Silling G, Ullmann A, Vehreschild MJGT, von Lilienfeld-Toal M, Wolf HH, Lehners N; German Society of Hematology and Medical Oncology Infectious Diseases Working Group (AGIHO).

Ann Oncol. 2018 Jun 1;29(6):1354-1365. doi: 10.1093/annonc/mdy117.

15.

Chlorhexidine-containing dressings in the prevention of central venous catheter-related bloodstream infections: A cost and resource utilization analysis.

Heimann SM, Biehl LM, Vehreschild JJ, Franke B, Cornely OA, Vehreschild MJGT.

Am J Infect Control. 2018 Sep;46(9):992-997. doi: 10.1016/j.ajic.2018.03.006. Epub 2018 Apr 13.

PMID:
29661631
16.

Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline.

Ullmann AJ, Aguado JM, Arikan-Akdagli S, Denning DW, Groll AH, Lagrou K, Lass-Flörl C, Lewis RE, Munoz P, Verweij PE, Warris A, Ader F, Akova M, Arendrup MC, Barnes RA, Beigelman-Aubry C, Blot S, Bouza E, Brüggemann RJM, Buchheidt D, Cadranel J, Castagnola E, Chakrabarti A, Cuenca-Estrella M, Dimopoulos G, Fortun J, Gangneux JP, Garbino J, Heinz WJ, Herbrecht R, Heussel CP, Kibbler CC, Klimko N, Kullberg BJ, Lange C, Lehrnbecher T, Löffler J, Lortholary O, Maertens J, Marchetti O, Meis JF, Pagano L, Ribaud P, Richardson M, Roilides E, Ruhnke M, Sanguinetti M, Sheppard DC, Sinkó J, Skiada A, Vehreschild MJGT, Viscoli C, Cornely OA.

Clin Microbiol Infect. 2018 May;24 Suppl 1:e1-e38. doi: 10.1016/j.cmi.2018.01.002. Epub 2018 Mar 12.

PMID:
29544767
17.

Guidance document for prevention of Clostridium difficile infection in acute healthcare settings.

Tschudin-Sutter S, Kuijper EJ, Durovic A, Vehreschild MJGT, Barbut F, Eckert C, Fitzpatrick F, Hell M, Norèn T, O'Driscoll J, Coia J, Gastmeier P, von Müller L, Wilcox MH, Widmer AF; Committee.

Clin Microbiol Infect. 2018 Oct;24(10):1051-1054. doi: 10.1016/j.cmi.2018.02.020. Epub 2018 Mar 2. Review.

PMID:
29505879
18.

Economic burden and cost-effective management of Clostridium difficile infections.

Heimann SM, Cruz Aguilar MR, Mellinghof S, Vehreschild MJGT.

Med Mal Infect. 2018 Feb;48(1):23-29. doi: 10.1016/j.medmal.2017.10.010. Epub 2018 Jan 12. Review.

PMID:
29336929
19.

Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial.

Guery B, Menichetti F, Anttila VJ, Adomakoh N, Aguado JM, Bisnauthsing K, Georgopali A, Goldenberg SD, Karas A, Kazeem G, Longshaw C, Palacios-Fabrega JA, Cornely OA, Vehreschild MJGT; EXTEND Clinical Study Group.

Lancet Infect Dis. 2018 Mar;18(3):296-307. doi: 10.1016/S1473-3099(17)30751-X. Epub 2017 Dec 19.

PMID:
29273269
20.

Diagnosis and management of gastrointestinal complications in adult cancer patients: 2017 updated evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).

Schmidt-Hieber M, Bierwirth J, Buchheidt D, Cornely OA, Hentrich M, Maschmeyer G, Schalk E, Vehreschild JJ, Vehreschild MJGT; AGIHO Working Group.

Ann Hematol. 2018 Jan;97(1):31-49. doi: 10.1007/s00277-017-3183-7. Epub 2017 Nov 24. Review.

21.

Impact of choice, timing, sequence and combination of broad-spectrum antibiotics on the outcome of allogeneic haematopoietic stem cell transplantation.

Farowski F, Bücker V, Vehreschild JJ, Biehl L, Cruz-Aguilar R, Scheid C, Holtick U, Jazmati N, Wisplinghoff H, Cornely OA, Vehreschild MJGT.

Bone Marrow Transplant. 2018 Jan;53(1):52-57. doi: 10.1038/bmt.2017.203. Epub 2017 Nov 13.

PMID:
29131156
22.

FungiScope -Global Emerging Fungal Infection Registry.

Seidel D, Durán Graeff LA, Vehreschild MJGT, Wisplinghoff H, Ziegler M, Vehreschild JJ, Liss B, Hamprecht A, Köhler P, Racil Z, Klimko N, Sheppard DC, Herbrecht R, Chowdhary A, Cornely OA, FungiScope Group.

Mycoses. 2017 Aug;60(8):508-516. doi: 10.1111/myc.12631.

PMID:
28730644
23.

Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia.

Cornely OA, Leguay T, Maertens J, Vehreschild MJGT, Anagnostopoulos A, Castagnola C, Verga L, Rieger C, Kondakci M, Härter G, Duarte RF, Allione B, Cordonnier C, Heussel CP, Morrissey CO, Agrawal SG, Donnelly JP, Bresnik M, Hawkins MJ, Garner W, Gökbuget N; AmBiGuard Study Group.

J Antimicrob Chemother. 2017 Aug 1;72(8):2359-2367. doi: 10.1093/jac/dkx133.

24.

Determination of a Cutoff Time Point for Prophylactic Exchange of Central Venous Catheters for Prevention of Central Venous Catheter-Related Bloodstream Infections in Patients with Hematological Malignancies.

Schalk E, Biehl LM, Färber J, Schlüter D, Vehreschild MJGT, Fischer T.

Infect Control Hosp Epidemiol. 2017 Jul;38(7):888-889. doi: 10.1017/ice.2017.92. Epub 2017 May 18. No abstract available.

PMID:
28514979
25.

Screening and contact precautions - A survey on infection control measures for multidrug-resistant bacteria in German university hospitals.

Biehl LM, Bertz H, Bogner J, Dobermann UH, Kessel J, Krämer C, Lemmen S, von Lilienfeld-Toal M, Peter S, Pletz MW, Rohde H, Schmiedel S, Schubert S, Ullmann AJ, Fätkenheuer G, Vehreschild MJGT.

Antimicrob Resist Infect Control. 2017 Apr 13;6:37. doi: 10.1186/s13756-017-0191-2. eCollection 2017.

26.

Invasive infections due to Saprochaete and Geotrichum species: Report of 23 cases from the FungiScope Registry.

Durán Graeff L, Seidel D, Vehreschild MJ, Hamprecht A, Kindo A, Racil Z, Demeter J, De Hoog S, Aurbach U, Ziegler M, Wisplinghoff H, Cornely OA; FungiScope Group.

Mycoses. 2017 Apr;60(4):273-279. doi: 10.1111/myc.12595. Epub 2017 Feb 2.

PMID:
28150341
27.

Serial assessment of pulmonary lesion volume by computed tomography allows survival prediction in invasive pulmonary aspergillosis.

Vehreschild JJ, Heussel CP, Groll AH, Vehreschild MJGT, Silling G, Würthwein G, Brecht M, Cornely OA.

Eur Radiol. 2017 Aug;27(8):3275-3282. doi: 10.1007/s00330-016-4717-4. Epub 2017 Jan 12.

PMID:
28083695
28.

Epidemiology of invasive aspergillosis and azole resistance in patients with acute leukaemia: the SEPIA Study.

Koehler P, Hamprecht A, Bader O, Bekeredjian-Ding I, Buchheidt D, Doelken G, Elias J, Haase G, Hahn-Ast C, Karthaus M, Kekulé A, Keller P, Kiehl M, Krause SW, Krämer C, Neumann S, Rohde H, La Rosée P, Ruhnke M, Schafhausen P, Schalk E, Schulz K, Schwartz S, Silling G, Staib P, Ullmann A, Vergoulidou M, Weber T, Cornely OA, Vehreschild MJ.

Int J Antimicrob Agents. 2017 Feb;49(2):218-223. doi: 10.1016/j.ijantimicag.2016.10.019. Epub 2016 Dec 12.

PMID:
27989379
29.

Disseminated Fusariosis in Immunocompromised Children-Analysis of Recent Cases Identified in the Global Fungiscope Registry.

Hassler A, Lieb A, Seidel D, Cesaro S, Greil J, Klimko N, Khostelidi S, Solopova G, Ogunc D, Durán Graeff L, Cornely OA, Vehreschild MJ, Lehrnbecher T.

Pediatr Infect Dis J. 2017 Feb;36(2):230-231. doi: 10.1097/INF.0000000000001396.

PMID:
27846057
30.

Draft Genome Sequences of Nine Clinical Isolates of Vancomycin-Resistant Enterococci.

Higgins PG, Koehler D, Chan JZ, Cornely OA, Fätkenheuer G, Gillis M, Pallen MJ, Tien J, Seifert H, Vehreschild MJ, Millard AD.

Genome Announc. 2016 Aug 18;4(4). pii: e00803-16. doi: 10.1128/genomeA.00803-16.

31.

The VITAL study: case control studies are hypothesis-generating - Authors' reply.

Cornely OA, Maher RM, Marty FM, Lee M, Vehreschild JJ, Vehreschild MJ.

Lancet Infect Dis. 2016 Aug;16(8):886-7. doi: 10.1016/S1473-3099(16)30192-X. No abstract available.

PMID:
27477971
32.

Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiota.

Pflug N, Kluth S, Vehreschild JJ, Bahlo J, Tacke D, Biehl L, Eichhorst B, Fischer K, Cramer P, Fink AM, von Bergwelt-Baildon M, Stilgenbauer S, Hallek M, Cornely OA, Vehreschild MJ.

Oncoimmunology. 2016 Apr 22;5(6):e1150399. doi: 10.1080/2162402X.2016.1150399. eCollection 2016 Jun.

33.

A randomized trial on chlorhexidine dressings for the prevention of catheter-related bloodstream infections in neutropenic patients.

Biehl LM, Huth A, Panse J, Krämer C, Hentrich M, Engelhardt M, Schäfer-Eckart K, Kofla G, Kiehl M, Wendtner CM, Karthaus M, Ullmann AJ, Hellmich M, Christ H, Vehreschild MJ.

Ann Oncol. 2016 Oct;27(10):1916-22. doi: 10.1093/annonc/mdw275. Epub 2016 Jul 25.

PMID:
27456299
34.

Editorial Commentary: Where to Place the New Treatments for Clostridium difficile Infection?

Cornely OA, Vehreschild MJ.

Clin Infect Dis. 2016 Sep 15;63(6):735-6. doi: 10.1093/cid/ciw366. Epub 2016 Jun 30. No abstract available.

35.

A cohort study on breakthrough invasive fungal infections in high-risk patients receiving antifungal prophylaxis.

Biehl LM, Vehreschild JJ, Liss B, Franke B, Markiefka B, Persigehl T, Bücker V, Wisplinghoff H, Scheid C, Cornely OA, Vehreschild MJ.

J Antimicrob Chemother. 2016 Sep;71(9):2634-41. doi: 10.1093/jac/dkw199. Epub 2016 Jun 17.

PMID:
27317443
36.

Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis.

Marty FM, Ostrosky-Zeichner L, Cornely OA, Mullane KM, Perfect JR, Thompson GR 3rd, Alangaden GJ, Brown JM, Fredricks DN, Heinz WJ, Herbrecht R, Klimko N, Klyasova G, Maertens JA, Melinkeri SR, Oren I, Pappas PG, Ráčil Z, Rahav G, Santos R, Schwartz S, Vehreschild JJ, Young JH, Chetchotisakd P, Jaruratanasirikul S, Kanj SS, Engelhardt M, Kaufhold A, Ito M, Lee M, Sasse C, Maher RM, Zeiher B, Vehreschild MJGT; VITAL and FungiScope Mucormycosis Investigators.

Lancet Infect Dis. 2016 Jul;16(7):828-837. doi: 10.1016/S1473-3099(16)00071-2. Epub 2016 Mar 9.

PMID:
26969258
37.

Fecal Microbiota Transfer 2.0.

Vehreschild MJ, Cornely OA.

J Infect Dis. 2016 Jul 15;214(2):169-70. doi: 10.1093/infdis/jiv768. Epub 2016 Feb 8. No abstract available.

38.

[Resistant fungi].

Vehreschild MJ, Cornely OA.

Internist (Berl). 2015 Nov;56(11):1271-6. doi: 10.1007/s00108-015-3704-1. Review. German.

PMID:
26432089
39.

First implementation of frozen, capsulized faecal microbiota transplantation for recurrent Clostridium difficile infection into clinical practice in Europe.

Tacke D, Wisplinghoff H, Kretzschmar A, Farowski F, Koehler P, Herweg J, Cornely OA, Vehreschild MJ.

Clin Microbiol Infect. 2015 Nov;21(11):e82-4. doi: 10.1016/j.cmi.2015.06.027. Epub 2015 Jul 8. No abstract available.

40.

Economic burden of Clostridium difficile associated diarrhoea: a cost-of-illness study from a German tertiary care hospital.

Heimann SM, Vehreschild JJ, Cornely OA, Wisplinghoff H, Hallek M, Goldbrunner R, Böttiger BW, Goeser T, Hölscher A, Baldus S, Müller F, Jazmati N, Wingen S, Franke B, Vehreschild MJ.

Infection. 2015 Dec;43(6):707-14. doi: 10.1007/s15010-015-0810-x. Epub 2015 Jun 30.

PMID:
26123227
41.

Our 2015 approach to invasive pulmonary aspergillosis.

Liss B, Vehreschild JJ, Bangard C, Maintz D, Frank K, Grönke S, Michels G, Hamprecht A, Wisplinghoff H, Markiefka B, Hekmat K, Vehreschild MJ, Cornely OA.

Mycoses. 2015 Jun;58(6):375-82. doi: 10.1111/myc.12319. Epub 2015 Mar 24. Review.

PMID:
25808916
42.

Fungus-specific CD4(+) T cells for rapid identification of invasive pulmonary mold infection.

Bacher P, Steinbach A, Kniemeyer O, Hamprecht A, Assenmacher M, Vehreschild MJ, Vehreschild JJ, Brakhage AA, Cornely OA, Scheffold A.

Am J Respir Crit Care Med. 2015 Feb 1;191(3):348-52. doi: 10.1164/rccm.201407-1235LE. No abstract available.

PMID:
25635493
43.

Emergence of azole-resistant invasive aspergillosis in HSCT recipients in Germany.

Steinmann J, Hamprecht A, Vehreschild MJ, Cornely OA, Buchheidt D, Spiess B, Koldehoff M, Buer J, Meis JF, Rath PM.

J Antimicrob Chemother. 2015 May;70(5):1522-6. doi: 10.1093/jac/dku566. Epub 2015 Jan 27.

PMID:
25630644
44.

Different doses of micafungin for prophylaxis of invasive fungal diseases in hemato-oncological high-risk patients: a web-based non-interventional trial in four large university hospitals in Germany.

Heimann SM, Vehreschild MJ, Meintker L, Heinz W, Schroeder T, von Bergwelt-Baildon M, Cornely OA, Vehreschild JJ.

Transpl Infect Dis. 2014 Dec;16(6):968-74. doi: 10.1111/tid.12305. Epub 2014 Nov 5.

PMID:
25371351
45.

A cost and resource utilization analysis of micafungin bridging for hemato-oncological high-risk patients undergoing allogeneic stem cell transplantation.

Heimann SM, Vehreschild MJ, Cornely OA, Franke B, von Bergwelt-Baildon M, Wisplinghoff H, Kron F, Scheid C, Vehreschild JJ.

Eur J Haematol. 2015 Jun;94(6):526-31. doi: 10.1111/ejh.12466. Epub 2015 Feb 23.

PMID:
25310918
46.

Candidemia in the intensive care unit: analysis of direct treatment costs and clinical outcome in patients treated with echinocandins or fluconazole.

Heimann SM, Cornely OA, Wisplinghoff H, Kochanek M, Stippel D, Padosch SA, Langebartels G, Reuter H, Reiner M, Vierzig A, Seifert H, Vehreschild MJ, Glossmann J, Franke B, Vehreschild JJ.

Eur J Clin Microbiol Infect Dis. 2015 Feb;34(2):331-8. doi: 10.1007/s10096-014-2230-8. Epub 2014 Sep 12.

PMID:
25213718
47.

A multicentre cohort study on colonization and infection with ESBL-producing Enterobacteriaceae in high-risk patients with haematological malignancies.

Vehreschild MJ, Hamprecht A, Peterson L, Schubert S, Häntschel M, Peter S, Schafhausen P, Rohde H, Lilienfeld-Toal MV, Bekeredjian-Ding I, Libam J, Hellmich M, Vehreschild JJ, Cornely OA, Seifert H.

J Antimicrob Chemother. 2014 Dec;69(12):3387-92. doi: 10.1093/jac/dku305. Epub 2014 Aug 6.

PMID:
25103492
48.

[Azole resistance in Aspergillus fumigatus - epidemiology and detection in immunocompromised patients in Germany].

Buchheidt D, Spiess B, Cornely OA, Vehreschild MJ, Hamprecht A, Rath PM, Steinmann J, Groß U, Bader O, Lauten M, Reinwald M, Hofmann WK.

Dtsch Med Wochenschr. 2014 Jun;139(25-26):1373-6. doi: 10.1055/s-0034-1370130. Epub 2014 Jun 10. Review. German. No abstract available.

PMID:
24914515
49.

Feasibility and effectiveness of posaconazole prophylaxis in combination with micafungin bridging for patients undergoing allogeneic stem cell transplantation: a 6-yr analysis from the cologne cohort for neutropenic patients.

Vehreschild MJ, von Bergwelt-Baildon M, Tran L, Shimabukuro-Vornhagen A, Wisplinghoff H, Bangard C, Cornely OA, Vehreschild JJ.

Eur J Haematol. 2014 Nov;93(5):400-6. doi: 10.1111/ejh.12368. Epub 2014 May 26.

PMID:
24798021
50.

PTX3 deficiency and aspergillosis.

Vehreschild JJ, Vehreschild MJ, Cornely OA.

N Engl J Med. 2014 Apr 24;370(17):1666. doi: 10.1056/NEJMc1402787. No abstract available.

PMID:
24758634

Supplemental Content

Loading ...
Support Center